Table 3. Change in EQ-5D-3L utility score after 2 years of follow-up.

	Mean change (95% CI)	Difference (95% CI)	P
Univariable analysis
Group 1	−0.03 (−0.06 to 0.00)	0.00 (−0.03 to 0.03)	0.826
Group 2	−0.13 (−0.18 to −0.08)	−0.10 (−0.15 to −0.04)	0.001
Group 3	−0.03 (−0.05 to −0.02)	Reference
Multivariable analysis (Model 1)
Group 1	−0.02 (−0.06 to 0.01)	−0.01 (−0.04 to 0.03)	0.701
Group 2	−0.08 (−0.14 to −0.02)	−0.06 (−0.13 to 0.00)	0.039
Group 3	−0.02 (−0.04 to 0.01)	Reference
Multivariable analysis (Model 2)
Group 1	−0.03 (−0.08 to 0.02)	−0.01 (−0.04 to 0.03)	0.710
Group 2	−0.09 (−0.16 to −0.02)	−0.06 (−0.12 to 0.00)	0.046
Group 3	−0.03 (−0.07 to 0.02)	Reference
Multivariable analysis (Model 3)
Group 1	−0.06 (−0.11 to −0.01)	−0.01 (−0.04 to 0.03)	0.637
Group 2	−0.15 (−0.22 to −0.09)	−0.10 (−0.16 to −0.04)	0.001
Group 3	−0.05 (−0.09 to −0.01)	Reference

Model 1: Adjusted for age, age at hemodialysis onset, sex, diabetic nephropathy, dialysis vintage, history of myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation, predialysis body mass index, Kt/V, geriatric nutritional risk index, hemoglobin, C-reactive protein, use of benzodiazepine agents.

Model 2: Adjusted for covariates in Model 1 plus new-onset myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation during follow-up.

Model 3: Adjusted for all factors in Model 2 except for Kt/V and C-reactive protein.

Abbreviations: CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire.